Abstract
Objectives: In response to reports of Trypanosoma brucei resistance to the nitroaromatic drug nifurtimox, we evaluated the potential of antituberculosis nitrofuran isoxazolines as inhibitors of trypanosome growth. Methods: The susceptibility of T. brucei brucei was assessed in vitro. The lowest effective concentration to inhibit growth (EC90) against drug-susceptible and -resistant parasites, time-kill kinetics, reversibility of inhibition and propensity for P-glycoprotein-mediated exclusion from the blood-brain barrier were determined. Results: Nitrofuran isoxazolines were potent inhibitors of T. brucei brucei proliferation at nanomolar concentrations, with pentacyclic nitrofurans being 100-fold more potent than nifurtimox. Activity was sustained against nifurtimox-resistant parasites, suggesting the possibility of a unique mechanism of activation and potential for use in the treatment of drug-resistant infections. Exposure of parasites to the maximum concentrations of Compound 15 achieved in vivo with oral dosing yielded >2 logs of irreversible killing in <4 h, indicating rapid trypanocidal activity. Conclusions: Pentacyclic nitrofuran isoxazolines warrant further development for the treatment of drug-susceptible and nifurtimox-resistant trypanosome infections.
Original language | English |
---|---|
Pages (from-to) | 956-963 |
Number of pages | 8 |
Journal | Journal of Antimicrobial Chemotherapy |
Volume | 71 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1 2016 |
Bibliographical note
Publisher Copyright:© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Funding
This study was supported by the National Institutes of Health grants R01AI062145 and the American Lebanese Syrian Associated Charities (ALSAC), St Jude Children’s Research Hospital. A. H. F. and S.W. are funded by the Wellcome Trust (079838).
Funders | Funder number |
---|---|
National Institutes of Health (NIH) | R01AI062145 |
St. Jude Children's Research Hospital | |
Wellcome Trust | 079838 |
American Lebanese Syrian Associated Charities |
ASJC Scopus subject areas
- Pharmacology
- Microbiology (medical)
- Pharmacology (medical)
- Infectious Diseases